Current cardiovascular research often focuses on nitric oxide (NO) bioavailability and microcirculatory function. Enzymatic processes within erythrocytes can influence vascular tone under pathological conditions.

This represents a regulatory imbalance, not a malfunctioning cell type.

Modulating biochemical pathways differs fundamentally from disabling cellular functions. NO signalling operates within a tightly regulated physiological range. Interventions that oversimplify this balance risk unintended consequences.

Understanding the distinction between modulation and suppression is essential when translating laboratory findings into clinical narratives.